Inusa Jafaru Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 475 Highway 49, Sutter Creek, CA 95685 Phone: 209-267-5128 Fax: 209-267-9146 |
Tanya Mew Hou Lee Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 475 Highway 49, Sutter Creek, CA 95685 Phone: 209-267-5128 |
Robert Calandri Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 284 Ursula Dr, Sutter Creek, CA 95685 Phone: 209-274-4911 |
Robert Yu, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 475 State Highway 49, Sutter Creek, CA 95685 Phone: 209-267-5128 Fax: 209-267-9146 |
Truong Tang Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 475 State Highway 49, Sutter Creek, CA 95685 Phone: 209-267-5128 Fax: 209-267-9146 |
Kayla Fillmore Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 475 State Highway 49, Sutter Creek, CA 95685 Phone: 209-267-5128 Fax: 209-267-9146 |
Khang Minh Vo, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 475 State Highway 49, Sutter Creek, CA 95685 Phone: 209-267-5128 |
Isaak Mercado Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 475 Ca-49, Sutter Creek, CA 95685 Phone: 209-267-5128 |
News Archive
Heredity plays a major role in determining the blood lipid profile and heart rate variability of blacks and whites, two major risk factors for coronary artery disease, researchers say.
People from northern and southern Sweden differ from each other genetically, according to the largest genetic study of the Swedish population yet. Swedes also have genetically more in common with Germans and British than with Finns. The study, performed jointly at Karolinska Institutet in Sweden and University of Helsinki, has been published in PLoS ONE.
CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.
Qioptiq, an Excelitas Technologies® Company and global technology leader focused on delivering innovative optical and photonic solutions, introduces the new 1.73x Tube Lens as a widely desired addition to the mag.x system 125.
Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient prognosis and therapy resistance.
› Verified 6 days ago